Literature DB >> 16356089

Hypothyroidism might be related to breast cancer in post-menopausal women.

Johannes L P Kuijpens1, Ivan Nyklíctek, Marieke W J Louwman, Tony A P Weetman, Victor J M Pop, Jan-Willem W Coebergh.   

Abstract

An association between breast cancer and thyroid (autoimmune) diseases or the presence of thyroid peroxidase antibodies (TPOAb; a marker of thyroid autoimmune disease) has been suggested. However, little is known about whether women with thyroid (autoimmune) diseases are at increased risk for developing breast cancer. This cross-sectional and prospective cohort study investigated whether the presence of TPOAb or thyroid dysfunction is related to the presence or development of breast cancer. An unselected cohort of 2,775 women around menopause was screened for the thyroid parameters thyrotropin (TSH), free thyroxine (FT(4)), and TPOAb during 1994. Detailed information on previous or actual thyroid disorders and breast cancer, and on putative factors related to breast cancer and thyroid disorders, was obtained. Clinical thyroid dysfunction was defined by both abnormal FT4 and TSH, and subclinical thyroid dysfunction by abnormal TSH (with normal FT4). A TPOAb concentration >or= 100 U/ml was defined as positive (TPOAb(+)). The study group was linked with the Eindhoven Cancer Registry to detect all women with (in situ) breast cancer (ICD-O code 174) diagnosed between 1958 and 1994. Subsequently, in the prospective study, all women who did not have breast cancer in 1994 (n = 2,738) were followed up to July, 2003, and all new cases of (in situ) breast cancer and all cancer-related deaths were registered. Of the 2,775 women, 278 (10.0%) were TPOAb(+). At the 1994 screening, 37 women (1.3%) had breast cancer. TPOAbs were (independently) related to a current diagnosis of breast cancer (OR = 3.3; 95% CI 1.3-8.5). Of the remaining women, 61 (2.2%) developed breast cancer. New breast cancer was related to: (1) an earlier diagnosis of hypothyroidism (OR = 3.8; 95% CI 1.3-10.9); (2) the use of thyroid medication (OR = 3.2; 95% CI 1.0-10.7); and (3) low FT4 (lowest tenth percentile: OR = 2.3; 95% CI 1.2-4.6). In the first 3 years follow up, the relationship between FT4 and log-TSH was disturbed in women with a new breast cancer diagnosis. The presence of TPOAb was not related to breast cancer during follow-up. A direct relationship between thyroid autoimmunity and breast cancer is unlikely. Hypothyroidism and low-normal FT4 are related with an increased risk of breast cancer in post-menopausal women. Studies are needed to clarify the origins of this possible association.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356089     DOI: 10.1089/thy.2005.15.1253

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  41 in total

1.  Inhibition of STAT3 signaling blocks obesity-induced mammary hyperplasia in a mouse model.

Authors:  Jeong Won Park; Li Zhao; Mark C Willingham; Sheue-Yann Cheng
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer.

Authors:  Aurelia Vattai; Elif Akyol; Christina Kuhn; Simone Hofmann; Helene Heidegger; Franz von Koch; Kerstin Hermelink; Rachel Wuerstlein; Nadia Harbeck; Doris Mayr; Christine Spitzweg; Bettina Toth; Sven Mahner; Udo Jeschke; Nina Ditsch
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-13       Impact factor: 4.553

3.  Urinary Iodine Concentration and Mortality Among U.S. Adults.

Authors:  Kosuke Inoue; Angela M Leung; Takehiro Sugiyama; Tetsuro Tsujimoto; Noriko Makita; Masaomi Nangaku; Beate R Ritz
Journal:  Thyroid       Date:  2018-07       Impact factor: 6.568

4.  Hypothalamus-pituitary-thyroid axis disruption in rats with breast cancer is related to an altered endogenous oxytocin/insulin-regulated aminopeptidase (IRAP) system.

Authors:  María Pilar Carrera-González; María Jesús Ramírez-Expósito; Jose Manuel Arias de Saavedra; Rafael Sánchez-Agesta; María Dolores Mayas; Jose Manuel Martínez-Martos
Journal:  Tumour Biol       Date:  2011-01-05

5.  Thyroid function: Thyroid dysfunction and breast cancer risk - an unfinished story.

Authors:  Layal Chaker; Theo J Visser
Journal:  Nat Rev Endocrinol       Date:  2016-03-29       Impact factor: 43.330

6.  Thyroid dysfunction, thyroid hormone replacement and colorectal cancer risk.

Authors:  Ben Boursi; Kevin Haynes; Ronac Mamtani; Yu-Xiao Yang
Journal:  J Natl Cancer Inst       Date:  2015-04-08       Impact factor: 13.506

Review 7.  Does thyroid dysfunction increase the risk of breast cancer? A systematic review and meta-analysis.

Authors:  Y Fang; L Yao; J Sun; R Yang; Y Chen; J Tian; K Yang; L Tian
Journal:  J Endocrinol Invest       Date:  2017-05-17       Impact factor: 4.256

8.  TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001).

Authors:  Ilaria Muller; Lucy S Kilburn; Peter N Taylor; Peter J Barrett-Lee; Judith M Bliss; Paul Ellis; Marian E Ludgate; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2017-04-04

9.  Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer.

Authors:  E Fiore; E Giustarini; C Mammoli; F Fragomeni; D Campani; I Muller; A Pinchera; C Giani
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

10.  Breast cancer and thyroid diseases: analysis of 867 consecutive cases.

Authors:  C Chiappa; F Rovera; S Rausei; S Del Ferraro; A Fachinetti; M Lavazza; V Marchionini; V Arlant; M L Tanda; E Piantanida; H Y Kim; A Anuwong; G Dionigi
Journal:  J Endocrinol Invest       Date:  2016-09-13       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.